← Beam Therapeutics Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $37.2m | $162.2m | $560.0m | $232.8m | $435.9m | $282.0m | $294.9m | |
| Prepaid expenses and other current assets | $2.7m | $8.7m | $7.4m | $14.8m | $21.2m | $27.4m | $23.5m | |
| Total current assets | $94.5m | $308.3m | $1.3b | $1.1b | $1.2b | $878.1m | $1.3b | |
| Property and equipment, net | $24.3m | $38.5m | $84.3m | $115.6m | $125.0m | $111.4m | $104.5m | |
| Operating lease right-of-use assets | $19.0m | $86.9m | $102.7m | $118.5m | $112.8m | $104.9m | $100.7m | |
| Other assets | $5.0m | $3.1m | $1.7m | $1.9m | $2.1m | $1.3m | $634k | |
| Marketable securities | $54.6m | $137.5m | $405.7m | $845.4m | $754.0m | $568.8m | $950.3m | |
| Restricted cash | $13.3m | $14.8m | $12.7m | $12.8m | $8.7m | $8.1m | $6.7m | |
| Accrued expenses and other current liabilities | $7.9m | $18.5m | $28.9m | $48.1m | $111.7m | $47.5m | $55.3m | |
| Current portion of derivative liabilities | $7.8m | $71.2m | $42.2m | $18.3m | $10.8m | $8.4m | $7.7m | |
| Current portion of lease liability | $4.3m | $4.2m | $7.5m | $10.4m | $12.8m | $13.5m | $14.4m | |
| Current portion of contingent consideration liabilities | — | — | — | — | — | — | $2.7m | |
| Long-term lease liability | $21.2m | $96.0m | $134.8m | $168.6m | $159.9m | $148.0m | $139.8m | |
| Long-term portion of contingent consideration liabilities | — | — | $31.4m | $12.5m | $2.7m | $1.1m | $6.0m | |
| Long-term portion of deferred revenue | — | $394k | $262.3m | $202.2m | $109.9m | $33.2m | $0 | |
| Long-term portion of derivative liabilities | — | — | — | — | — | $5.4m | $0 | |
| Other liabilities | $418k | $2.5m | $2.8m | $224k | $298k | $504k | $173k | |
| Total assets | $156.1m | $451.7m | $1.5b | $1.3b | $1.5b | $1.1b | $1.5b | |
| Total liabilities and stockholders' equity | $156.1m | $451.7m | $1.5b | $1.3b | $1.5b | $1.1b | $1.5b | |
| Accounts payable | $7.8m | $6.3m | $7.5m | $9.0m | $1.6m | $3.9m | $10.2m | |
| Current portion of deferred revenue | — | $24k | $86.3m | $136.0m | $68.7m | $108.9m | $6.7m | |
| Total current liabilities | $29.1m | $102.3m | $213.4m | $223.6m | $205.6m | $182.1m | $96.9m | |
| Total liabilities | $55.2m | $206.1m | $647.7m | $608.2m | $478.4m | $370.3m | $242.8m | |
| Common stock, $0.01 par value; 250,000,000 shares authorized, 101,748,962 and 83,633,069 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 73k | 573k | 684k | 712k | 816k | 836k | 1.0m | |
| Additional paid-in capital | $1.9m | $642.6m | $1.6b | $1.8b | $2.2b | $2.3b | $2.9b | |
| Accumulated other comprehensive (loss) income | $16k | ($9k) | ($50k) | ($2.4m) | $604k | $679k | $1.1m | |
| Accumulated deficit | ($203.0m) | ($397.6m) | ($768.3m) | ($1.1b) | ($1.2b) | ($1.6b) | ($1.6b) | |
| Total stockholders' equity | ($201.1m) | $245.6m | $826.7m | $733.5m | $981.3m | $733.5m | $1.2b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.